Back to top
more

Celgene Corporation (CELG)

(Delayed Data from NSDQ)

$96.88 USD

96.88
5,654,306

+1.67 (1.75%)

Updated May 3, 2019 04:00 PM ET

After-Market: $96.84 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks News

J&J's (JNJ) Darzalex Faspro Gets FDA Nod for Amyloidosis

J&J (JNJ) gets accelerated approval for a new indication of Darzalex Faspro in combination with bortezomib, cyclophosphamide and dexamethasone for treating amyloidosis patients.

Fate Therapeutics Surges on Immunotherapy Deal With J&J

Fate Therapeutics (FATE) signs agreement with J&J subsidiary to develop CAR NK and CAR T-cell product candidates for cancer. The deal is likely tocreate significant future revenue stream for the company.

Sweta Killa headshot

Biotech ETFs Hit New Highs on Deal Activities

Following the new deals in the healthcare space, a few biotech ETFs hit new highs.

Bristol-Myers' Melanoma Study Misses Goal, Closes Celgene Deal

Bristol-Myers' (BMY) late-stage study evaluating the Opdivo-Yervoy combo fails to meet a co-primary endpoint of recurrence-free survival in melanoma patients. The company wraps up Celgene acquisition.

Sweta Killa headshot

Biotech ETF (BBH) Hits New 52-Week High

This biotech ETF hits a new 52-week high. Are more gains in store for this ETF?

Biotech Stock Roundup: MYOV & KRTX Surge, Pipeline Updates From VRTX, CELG & More

Key highlights of the past week include regulatory and pipeline updates along with collaboration deals.

Top Ranked Growth Stocks to Buy for November 20th

Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, November 20th

Celgene's Revlimid-Rituximab Combo Gets Positive CHMP Opinion

Celgene (CELG) gets a positive CHMP opinion, recommending the approval of Revlimid in combination with Rituxan for the treatment of adult patients with previously treated FL.

Bristol-Myers Gets FTC Clearance for Celgene Acquisition

Bristol-Myers (BMY) obtains FTC permission for the Celgene acquisition and will divest Otezla to Amgen.

Top Ranked Growth Stocks to Buy for November 18th

Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, November 18th.

Top Ranked Growth Stocks to Buy for November 14th

Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, November 14th

Biotech Stock Roundup: SLDB Plunges, CELG Gets FDA Nod for Reblozyl & Other Updates

Key highlights of the past week include regulatory and pipeline updates along with collaboration deals.

Editas (EDIT) Beats on Q3 Earnings, Amends Celgene Deal

Editas' (EDIT) portfolio currently lacks an approved product. The focus of third-quarter earnings call was on its pipeline development.

The Zacks Analyst Blog Highlights: Coherus, Incyte, ACADIA and Celgene

The Zacks Analyst Blog Highlights: Coherus, Incyte, ACADIA and Celgene

Top Ranked Growth Stocks to Buy for November 12th

Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, November 12th

4 Biotech Stocks That Could Keep Beating Wall Street

The biotechnology industry has lagged the broader market so far this year, but these four stocks have done pretty well and should continue to do so.

Celgene (CELG) Hits 52-Week High, Can the Run Continue?

Celgene (CELG) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Celgene & Acceleron Get FDA Nod for Rare Blood Disorder Drug

Celgene (CELG) and partner Acceleron obtain FDA approval for Reblozyl for the treatment of anemia in adult patients with beta thalassemia.

Corcept (CORT) Earnings Beat in Q3, Korlym Boosts Sales

Corcept (CORT) rides high on both earnings and revenue beat in the third quarter.

Prothena (PRTA) Reports Narrower-than-Expected Loss in Q3

Prothena (PRTA) posts a narrower Q3 loss while sales surpass estimates.

Will Celgene (CELG) Gain on Rising Earnings Estimates?

Celgene (CELG) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Celgene (CELG) Is Up 3.16% in One Week: What You Should Know

Does Celgene (CELG) have what it takes to be a top stock pick for momentum investors? Let's find out.

Is Celgene (CELG) Outperforming Other Medical Stocks This Year?

Is (CELG) Outperforming Other Medical Stocks This Year?

CELG vs. TECH: Which Stock Is the Better Value Option?

CELG vs. TECH: Which Stock Is the Better Value Option?

3 Reasons Why Celgene (CELG) Is a Great Growth Stock

Celgene (CELG) possesses solid growth attributes, which could help it handily outperform the market.